Aptamers are artificial nucleic acid ligands that can be engineered to bind with high specificity to a macromolecule. Their binding specificity and small size allow for a range of therapeutic applications. One avenue of research is to develop aptamers with specific and strong affinity to the HIV-1 envelope glycoprotein gp120 and act as novel HIV-1 entry inhibitor drugs or as targeted drug delivery systems to HIV-1 infected cells. Prior to any downstream applications, novel gp120 aptamers need to be biophysically characterised with regards to their target binding characteristics.
Reference:
Millroy, L, London, G, Veale, R et al. 2011. Binding kinetics of aptamers to gp120 derived from HIV-1 subtype C. EMBO global exchange lecture course on HIV AIDS, Stellenbsoch, 30 January - 04 February 2011
Millroy, L., London, G., Veale, R., Weinberg, M., & Khati, M. (2011). Binding kinetics of aptamers to gp120 derived from HIV-1 subtype C. Conference Poster. http://hdl.handle.net/10204/5155
Millroy, L, G London, R Veale, M Weinberg, and M Khati. "Binding kinetics of aptamers to gp120 derived from HIV-1 subtype C." (2011): http://hdl.handle.net/10204/5155
Millroy L, London G, Veale R, Weinberg M, Khati M, Binding kinetics of aptamers to gp120 derived from HIV-1 subtype C; Conference Poster; 2011. http://hdl.handle.net/10204/5155 .
